Talking with Bob Rappaport, former director, Division of Anesthesia, Analgesia, and Addiction Products, Office of New Drugs, Center for Drug Evaluation and Research, FDA. Dr. Rappaport retired from government service September, 2014.
Recent Posts
- SmartTots and the Power of Scientific Public–Private Partnerships with the US Food and Drug Administration
- A Scoping Review of the Mechanisms Underlying Developmental Anesthetic Neurotoxicity
- 2025 Annual Meeting, presented by the International Anesthesia Research Society (IARS) and the Society of Critical Care Anesthesiologists (SOCCA), March 20 – 23, 2025, Honolulu, HI
- Exposure to Operative Anesthesia in Childhood and Subsequent Neurobehavioral Diagnoses: A Natural Experiment Using Appendectomy
- Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial. Claire Elizabeth Wainwright, et al. June 2024